BRAINSWAY LTD/S’s Lock-Up Period Will Expire Tomorrow (NASDAQ:BWAY)

Share on StockTwits

BRAINSWAY LTD/S’s (NASDAQ:BWAY) lock-up period will end on Monday, October 14th. BRAINSWAY LTD/S had issued 2,500,000 shares in its IPO on April 17th. The total size of the offering was $27,500,000 based on an initial share price of $11.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Separately, Zacks Investment Research lowered shares of BRAINSWAY LTD/S from a “hold” rating to a “sell” rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. BRAINSWAY LTD/S currently has a consensus rating of “Buy” and a consensus price target of $15.80.

NASDAQ:BWAY opened at $9.00 on Friday. BRAINSWAY LTD/S has a one year low of $8.00 and a one year high of $12.39. The business’s 50-day simple moving average is $9.95.

BRAINSWAY LTD/S (NASDAQ:BWAY) last posted its quarterly earnings data on Monday, August 26th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.06). The company had revenue of $5.70 million for the quarter, compared to analyst estimates of $5.30 million. On average, analysts expect that BRAINSWAY LTD/S will post -0.52 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of BWAY. ARK Investment Management LLC purchased a new position in BRAINSWAY LTD/S in the second quarter worth about $863,000. Delek Group Ltd. purchased a new position in BRAINSWAY LTD/S in the second quarter worth about $3,176,000. Victory Capital Management Inc. purchased a new position in BRAINSWAY LTD/S in the second quarter worth about $157,000. Finally, Noked Capital LTD purchased a new position in BRAINSWAY LTD/S in the second quarter worth about $572,000. 10.84% of the stock is owned by institutional investors and hedge funds.

BRAINSWAY LTD/S Company Profile

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Read More: What is channel trading?

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.